🔴 Harmony Biosciences is trading 4.21% down in pre-market

Harmony Biosciences is trading 4.21% down at $35.46 in pre-market; no earnings results explaining the move were verified in available reports.

• The company scheduled its third-quarter results and investor call for November 4 at 8:30 a.m. ET.
• A report dated November 4 says the FDA expanded Wakix’s use for cataplexy, but that positive development does not explain the decline.
• The supplied market indices are higher, so broad-market weakness does not appear to account for the drop.